Anixa Biosciences, Inc. (NIX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anixa Biosciences, Inc. ("Anixa" or "the Company") (NASDAQ: NIX). The investigation concerns whether Anixa and certain of its officers and/or directors have violated federal securities laws.
On April 19, 2021, Anixa issued a press release “announc[ing] . . . that the U.S. Food and Drug Administration (US FDA) has requested additional information regarding its Chimeric Antigen Receptor-T cell therapy (CAR-T) being developed in partnership with Moffitt Cancer Center (MCC).” Anixa stated that “[t]he study under the Investigational New Drug (IND) application has been placed on clinical hold pending submission of additional information requested by the FDA. Within the next 30 days, it is expected that the FDA will provide a letter to MCC with detailed and specific information requested. MCC will assemble and submit information addressing the request as soon as possible thereafter. Successive to the submission, the FDA will continue its review of the IND.” On this news, Anixa’s stock price fell $0.64 per share, or 13.62%, to close at $4.06 per share on April 19, 2021.
If you are aware of any facts relating to this investigation, or purchased Anixa shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.